Jenny Barnett

Company: Monument Therapeutics

Job title: Chief Executive Officer

Seminars:

Demonstrating the Potential of Digital Biomarkers to Overcome Heterogeneity & Select Specific Schizophrenic Subpopulations 2:00 pm

Introducing personalized treatment strategies in psychosis drug development by identifying patient subgroups based on digital biomarkers and clinical characteristics Reducing trial size and time by focusing on populations most likely to respond, enhancing drug efficacy, and minimizing adverse effects, especially in cases where traditional antipsychotics failRead more

day: Day One